Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide

Molecular Pharmaceutics

Volumn 12, Issue 11, 2015, Pages 4166-4173

  Malm Erjefält, Monika ^a   Ekblom, Marianne ^a   Vouis, Jan ^b   Zdravkovic, Milan ^a   Lennernäs, Hans ^c  

^a NOVO NORDISK A S   (Denmark)

^b IQVIA   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

biopharmaceutical classification system; drug interaction; gastrointestinal absorption; GLP 1 receptor agonist; liraglutide

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; DIGOXIN; GRISEOFULVIN; LIRAGLUTIDE; LISINOPRIL; PLACEBO; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; CARDIOTONIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; COLD; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFECT; DRUG EXPOSURE; DRUG PENETRATION; DRUG SOLUBILITY; DRUG WITHDRAWAL; FATIGUE; FEELING COLD; FEMALE; GASTROINTESTINAL ABSORPTION; HEADACHE; HUMAN; INVESTIGATIVE PROCEDURES; LOADING DRUG DOSE; MALE; NAUSEA; NORMAL HUMAN; PELVIS FRACTURE; PH MEASUREMENT; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECOMMENDED DRUG DOSE; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; STOMACH PH; TONSILLITIS; VOMITING; WEIGHT REDUCTION; ADOLESCENT; CLASSIFICATION; COMPUTER SIMULATION; DRUG INTERACTION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; STOMACH EMPTYING; THERAPEUTIC EQUIVALENCE; TISSUE DISTRIBUTION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; ANTIHYPERTENSIVE AGENTS; ATORVASTATIN CALCIUM; BIOPHARMACEUTICS; CARDIOTONIC AGENTS; COMPUTER SIMULATION; CROSS-OVER STUDIES; DIGOXIN; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; GASTRIC EMPTYING; GASTROINTESTINAL ABSORPTION; GRISEOFULVIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; LISINOPRIL; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84946594292     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00278     Document Type: Article

References (33)

1. Rigato, M.; Fadini, G. P. Comparative effectiveness of liraglutide in the treatment of type 2 diabetes Diabetes, Metab. Syndr. Obes.: Targets Ther. 2014, 18, 107-120 10.2147/DMSO.S37644
2. Food and Drug Administration (FDA). Victoza prescribinginformation. http://www.accessdata.fda.gov/drugsatfda
3. European Medicines Agency (EMA). Summary of product characteristics- Victoza. http://www.emea.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/001026/WC500050017.pdf. Accessed date April 9 2015.
4. Glerup, H.; Bluhme, H.; Villadsen, G. E.; Rasmussen, K.; Ejskjaer, N.; Dahlerup, J. F. Gastric emptying: a comparison of three methods Scand. J. Gastroenterol. 2007, 42, 1182-1186 10.1080/00365520701370922
5. Flint, A.; Kapitza, C.; Hindsberger, C.; Zdravkovic, M. The once-daily human GLP-1 analog liraglutide improves postprandial and fasting glucose levels in type 2 diabetes patients Adv. Ther. 2011, 28, 213-226 10.1007/s12325-010-0110-x
6. Jelsing, J.; Vrang, N.; Hansen, G.; Raun, K.; Tang-Christensen, M.; Knudsen, L. B. Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight Diabetes, Obes. Metab. 2012, 14, 531-538 10.1111/j.1463-1326.2012.01557.x
7. Amidon, K. S.; Langguth, P.; Lennernäs, H.; Yu, L.; Amidon, G. L. Bioequivalence of oral products and the biopharmaceutic classification system: science, regulation, and public policy Clin. Pharmacol. Ther. 2011, 90, 467-470 10.1038/clpt.2011.109
8. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 1995, 12, 413-420 10.1023/A:1016212804288
9. Wu, C. Y.; Benet, L. Z. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system Pharm. Res. 2005, 22, 11-23 10.1007/s11095-004-9004-4
10. Griseofulvin drug information. Available at: http://www.mims.com/USA/drug/info/Griseofulvin%20Suspension/?type=full. Accessed date April 9 2015.
11. Schjoldager, B. T.; Mortensen, P. E.; Christiansen, J.; Orskov, C.; Holst, J. J. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans Dig. Dis. Sci. 1989, 34, 703-708 10.1007/BF01540341
12. O'Halloran, D. J.; Nikou, G. C.; Kreymann, B.; Ghatei, M. A.; Bloom, S. R. Glucagon-like peptide-1 (7-36)-NH2: a physiological inhibitor of gastric acid secretion in man J. Endocrinol. 1990, 126, 169-173 10.1677/joe.0.1260169
13. Atorvastatin SPC. Available at: http://www.medicines.org.uk/emc/medicine/1424/SPC/. Accessed April 9 2015.
14. Lisinopril SPC. Available at: https://www.medicines.org.uk/emc/medicine/23998. Accessed date April 9 2015.
15. Digoxin SPC. Available at: https://www.medicines.org.uk/emc/medicine/23944. Accessed date April 9 2015.
16. Declaration of Helsinki. Available at: http://www.wma.net/en/30publications/10policies/b3/17c.pdf. Accessed date April 9 2015.
17. Agersø, H.; Jensen, L. B.; Elbrønd, B.; Rolan, P.; Zdravkovic, M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men Diabetologia 2002, 45, 195-202 10.1007/s00125-001-0719-z
18. Chatterjee, D. J.; Khutoryansky, N.; Zdravkovic, M.; Sprenger, C. R.; Litwin, J. S. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes J. Clin. Pharmacol. 2009, 49, 1353-1362 10.1177/0091270009339189
19. Jiang, J.; Zhang, J.; Jacobsen, L. V.; Hu, P. The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous administration in healthy Chinese male subjects J. Clin. Pharmacol. 2011, 51, 1620-1627 10.1177/0091270010389468
20. Ahmed, I. S.; Aboul-Einien, M. H.; Mohamed, O. H.; Farid, S. F. Relative bioavailability of griseofulvin lyophilized dry emulsion tablet vs. immediate release tablet: a single-dose, randomized, open-label, six-period, crossover study in healthy adult volunteers in the fasted and fed states Eur. J. Pharm. Sci. 2008, 35, 219-225 10.1016/j.ejps.2008.07.002
21. Sjögren, E.; Abrahamsson, B.; Augustijns, P. et al. In vivo methods for drug absorption-comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects Eur. J. Pharm. Sci. 2014, 57, 99-151 10.1016/j.ejps.2014.02.010
22. Kapitza, C.; Zdravkovic, M.; Hindsberger, C.; Flint, A. The effect of the once-daily human glucagon-like peptide-1 analog liraglutide on the pharmacokinetics of acetaminophen Adv. Ther. 2011, 28, 650-660 10.1007/s12325-011-0044-y
23. Jacobsen, L.; Vouis, J.; Hindsberger, C.; Zdravkovic, M. Treatment With Liraglutide-a Once-Daily GLP-1 Analog-Does Not Reduce the Bioavailability of Ethinyl Estradiol/Levonorgestrel Taken as an Oral Combination Contraceptive Drug J. Clin. Pharmacol. 2011, 51, 1696-703 10.1177/0091270010389471
24. Kothare, P. A.; Seger, M. E.; Northrup, J.; Mace, K.; Mitchell, M. I.; Linnebjerg, H. Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial BMC Clin. Pharmacol. 2012, 12, 8 10.1186/1472-6904-12-8
25. Food and Drug Administration (FDA). Byetta SPC. https://www.medicines.org.uk/emc/medicine/19257. Accessed date April 9 2015.
26. Soon, D.; Linnebjerg, H.; Kothare, P. A. et al. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men J. Clin. Pharmacol. 2006, 46, 1179-1187 10.1177/0091270006291622
27. Kothare, P. A.; Linnebjerg, H.; Skrivanek, Z. et al. Exendatide effects on statin pharmacokinetics and lipid response Int. J. Clin. Pharmacol. Ther. 2007, 45, 114-120 10.5414/CPP45114
28. Linnebjerg, H.; Kothare, P.; Park, S.; Mace, K.; Mitchell, M. The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension Int. J. Clin. Pharmacol. Ther. 2009, 47, 651-658 10.5414/CPP47651
29. Kothare, P. A.; Soon, D.; Linnebjerg, H. et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin J. Clin. Pharmacol. 2005, 45, 1032-1037 10.1177/0091270005278806
30. Smith, T. W.; Haber, E. Digoxin intoxication: the relationship of clinical presentation to serum digoxin concentration J. Clin. Invest. 1970, 49, 2377-2386 10.1172/JCI106457
31. Jarolim, P. Serum biomarkers for heart failure Cardiovasc. Pathol. 2006, 15, 144-149 10.1016/j.carpath.2006.01.001
32. Marathe, C. S.; Rayner, C. K.; Jones, K. L.; Horowitz, M. Relationships between gastric emptying, postprandial glycemia, and incretin hormones Diabetes Care 2013, 36, 1396-1405 10.2337/dc12-1609
33. Drucker, D. J.; Buse, J. B.; Taylor, K. et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 2008, 372, 1240-1250 10.1016/S0140-6736(08)61206-4